ARTELO BIOSCIENCES, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
ARTELO BIOSCIENCES, INC. (ARTL) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $1.35 million for the 12-month period ending 2024-12-31, per its 8-K filed 2025-07-11.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2025-07-11
- ARTELO BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for the quarter ending 2024-12-31 was $0.00.
- ARTELO BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for the quarter ending 2024-09-30 was $1.35M.
- ARTELO BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for the quarter ending 2023-12-31 was $0.00.
- ARTELO BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for the quarter ending 2023-09-30 was $0.00.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 3 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 6 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 9 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 8-K 12 month − 10-Q 9 month · filed 2025-07-11 | $1.35M derived: sum of 2 quarters · filed 2025-07-11 | $1.35M 8-K · filed 2025-07-11 | |
| 2024-09-30 | $1.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.35M 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-13 | |||
| 2023-12-31 | $0.00 derived: 8-K 12 month − 10-Q 9 month · filed 2025-07-11 | $0.00 derived: sum of 2 quarters · filed 2025-07-11 | $1.21M 8-K · filed 2025-07-11 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.21M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $1.21M 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B |